Breast cancer: Hologic touts 'excellent' results from 7-year MammoSite registry

October 4, 2013 by Arezu Sarvestani

Women's health company Hologic releases final results from the 7-year MammoSite registry of breast cancer patients treated with breast brachytherapy.

Breast cancer: Hologic touts 'excellent' results from 7-year MammoSite registry

Massachusetts women's health company Hologic (NSDQ:HOLX) rang in Breast Cancer Awareness Month with the release of registry data from the MammoSite trial, a 7-year study of more than 1,400 patients treated with breast brachytherapy.

MammoSite therapy is a breast-conserving treatment that delivers targeted radiation to areas deemed most likely for the re-emergence of cancerous growth. The final analysis of patients in Hologic's registry found low rates of local recurrent, greater than 90% long-term cosmesis (retention of aesthetic appearance) and less than 10% toxicity, according to a company statement.

Sign up to get our free newsletters delivered right to your inbox.

The findings, including an analysis by the American Society of Breast Surgeons, largely confirmed previous results from MammoSite studies, showing that the therapy compares favorably to other forms of accelerated partial breast irradiation, Hologic said.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp